Table 1. Ongoing clinical trials including TME evaluation in OMD/OPD lung cancer.

Phase	ClinicalTrials.gov identifier	Setting	N	Treatment	Type of tumor sample	Primary endpoints	Secondary endpoints	Status
IIb	NCT04216121	OPD EGFR-mutant NSCLC	39	LAT (SBRT or surgery) + first line osimertinib	Surgical specimen1	PFS2	Time to next line systemic therapy; patterns of progression to LAT; QoL	Active, recruiting
II	NCT02759835	OPD EGFR-mutant NSCLC	37	LAT (surgery, RT, radiofrequency ablation) before or after the start of osimertinib(any line)	Surgical specimen1 Liquid biopsy	PFS, PFS2	RR, OS	Active, not recruiting
II	NCT03808662	OPD triple negative breast cancer or NSCLC	160	SBRT to all the OPD sites vs. SOC	Tissue biopsy2	PFS	OS	Active, recruiting
II	NCT04255836	OMD NSCLC	35	Durvalumab + first line (carboplatin + paclitaxel or cisplatin + pemetrexed) + SBRT	Tissue biopsy2	PFS	ORR, OS, Safety	Active, not recruiting
II/III	NCT02759783	Extracranial OMD prostate cancer, breast cancer or NSCLC	245	SOC +/− SBRT	Tissue biopsy2	PFS	OS, local lesion control, QoL, FFWMD	Active, not recruiting
II	NCT02316002	OMD NSCLC	51	Pembrolizumab after definitive therapy	Tissue biopsy or surgical specimen2	PFS		Active, not recruiting
III	NCT03391869	Stage IV NSCLC	270	Nivolumab + ipilimumab +/− LCT	Tissue biopsy or cytological sample2	OS; OS in OMD subgroup	PFS, TANM	Active, recruiting
III	NCT02076477	OMD NSCLC	420	CT (cisplatin + docetaxel or pemetrexed) + RT	Tissue biopsy or cytological sample2	RR	PFS	Active, recruiting
II	NCT03965468	OMD NSCLC	47	Durvalumab + carboplatin-paclitaxel + SBRT on all the metastatic sites + surgery or radical RT on the primary	Surgical specimen1	PFS	OS, OR, DoR, distant PFS	Active, recruiting
II	NCT03410043	Stage IIIB or IV EGFR-mutated NSCLC	143	Osimertinib +/− LAT (surgery and/or RT)	Surgicalspecimen1	PFS	OS; PFS in OMD subgroup; TANM; time to progression of target lesions	Active, recruiting
III	NCT03827577	OMD NSCLC	195	SOC +/− LAT of all metastatic sites and resection of the primary	Surgical specimen3	OS		Active, recruiting

¹, surgical specimen available if LAT is performed with surgery of the oligometastatic sites; ², baseline tissue biopsy, cytological sample or surgical specimen (either on primary tumor or on metastasis); ³, surgical specimen of primary and/or of all oligometastases. N, number; OPD, oligoprogressive disease; NSCLC, non-small cell lung cancer; LAT, local ablative therapy; SBRT, stereotactic body radiotherapy; PFS, progression free survival; PFS2, progression free survival (at second progression); QoL, quality of life; RT, radiotherapy; RR, response rate; OS, overall survival; SOC, standard of care; OMD, oligometastatic disease; ORR, overall response rate; FFWMD, freedom from widespread metastatic disease; LCT, Local Consolidation Therapy; TANM, Time to Appearance of New Metastases; CT, chemotherapy; OR, overall response; DoR, duration of response.